audeo oncology website, page-3

The website was actually live over the weekend, but got taking down before the Ann on Monday morning.

VAST will also be what any cap raise/ IPO will be helping support...

"In addition to the HyACT platform, we have exclusive rights to the VAST small molecule drug discovery technology, which will give us the ability to research and develop new anti-cancer drug candidates. This technology has been deployed in several collaborations with pharmaceutical companies and research institutes exploring its capability and application in non-cancer therapeutic areas.

We plan to initiate programs to study inflammation pathways associated with cancer stem cells and cancer metabolism with a target involved in HA synthesis and also run 'low cash burn' programs in allosteric modulation of family B G-protein coupled receptors, as well as opioid receptor agonists and ion channel inhibitors for pain."